Key result
The LOW-RAO trial is designed to evaluate whether low-molecular-weight heparin improves radial artery patency at 4 weeks compared to no treatment in 60 patients with radial artery occlusion.
Why the study?
There is no evidence-based therapy from randomized controlled trials for the treatment of radial artery occlusion after transradial catheterization.
Does low-molecular-weight heparin improve radial artery patency rate in patients with radial artery occlusion after transradial catheterization?
RCT (n=60)
Open-label
Does low-molecular-weight heparin improve radial artery patency rate in patients with radial artery occlusion after transradial catheterization?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a randomized trial to evaluate whether low-molecular-weight heparin improves radial artery patency in patients with radial artery occlusion following transradial catheterization.
Radial artery occlusion (RAO) is the commonest complication of transradial catheterization. There is no evidence-based therapy, in the frame of a randomized control study, for the treatment of RAO. The purpose of the LOW-RAO study is to question the hypothesis if low-molecular-weight heparin is effective in the treatment of RAO after transradial coronary catheterization (both angiography and percutaneous coronary intervention). It is a prospective, open label, randomized controlled trial that will randomize 60 patients with RAO, irrespective of symptoms, into two groups, one receiving anticoagulation with low-molecular-weight heparin and the other receiving no treatment. The primary end point is improvement in radial artery patency rate at 4 weeks after the procedure. Clinical trial registration number: NCT04196309 (ClinicalTrials.gov)
No takes yet. Share an insight, caveat, or question.
Didagelos et al. (2021) conducted an RCT in Radial artery occlusion (RAO) (n=60). Low-molecular-weight heparin vs. No treatment was evaluated on Improvement in radial artery patency rate at 4 weeks after the procedure. The LOW-RAO trial is designed to evaluate whether low-molecular-weight heparin improves radial artery patency at 4 weeks compared to no treatment in 60 patients with radial artery occlusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: